Zeev Estrov

40.7k citations

669 papers · 26.3k indexed · 6 hit papers · h-index 82

Hematology top 0.01%
Molecular Biology top 0.2%
Genetics top 0.01%
Oncology top 0.2%
Immunology top 0.5%

Co-authors: Hagop M. Kantarjian Stefan Faderl Moshe Talpaz Jörge E. Cortes Susan O’Brien Michael J. Keating Razelle Kurzrock Alessandra Ferrajoli
Topics: Acute Myeloid Leukemia Research (285 papers)Chronic Lymphocytic Leukemia Research (231 papers)Chronic Myeloid Leukemia Treatments (184 papers)
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: New England Journal of Medicine Circulation Journal of Clinical Investigation
Partner nations: United States Israel Canada

In The Last Decade

Zeev Estrov

652 papers receiving 25.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Biology of Chronic Myeloid Leukemia

1999 975 citations Stefan Faderl, Zeev Estrov et al. profile →
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

2010 847 citations Srđan Verstovšek, Hagop M. Kantarjian et al. profile →
Hepatocytes and Epithelial Cells of Donor Origin in Recipients of Peripheral-Blood Stem Cells

2002 611 citations Maher Albitar, Zeev Estrov et al. profile →
Adult Stem Cells for Tissue Repair — A New Therapeutic Concept?

2003 572 citations Zeev Estrov et al. profile →
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

2000 559 citations Hagop M. Kantarjian, Taghi Manshouri et al. Blood profile →
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

2006 515 citations Hagop M. Kantarjian, Guillermo Garcia‐Manero et al. Blood profile →

Peers

Countries citing papers authored by Zeev Estrov

Since Specialization

Citations

This map shows the geographic impact of Zeev Estrov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeev Estrov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeev Estrov more than expected).

Fields of papers citing papers by Zeev Estrov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeev Estrov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeev Estrov. The network helps show where Zeev Estrov may publish in the future.

Co-authorship network of co-authors of Zeev Estrov

This figure shows the co-authorship network connecting the top 25 collaborators of Zeev Estrov. A scholar is included among the top collaborators of Zeev Estrov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeev Estrov. Zeev Estrov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The role of therapy in the outcome of patients with myelofibrosis 2023 ·Cancer ·Lucia Masárová,Prithviraj Bose,Naveen Pemmaraju,Naval Daver,Koji Sasaki,Helen T. Chifotides,Lingsha Zhou,Hagop M. Kantarjian,Zeev Estrov,Srđan Verstovšek	3
2	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures 2022 ·Leukemia ·(unknown),Nikolaos Ioannou,Mariela Sivina,(unknown),Karen Clise-Dwyer,Ekaterina Kim,Dan Li,Qing Ma,Alessandra Ferrajoli,Zeev Estrov,William G. Wierda,Piers Patten,Alan G. Ramsay,Jan A. Burger	12
3	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia 2021 ·British Journal of Haematology ·(unknown),(unknown),Shilpa Paul,Xuemei Wang,Koji Sasaki,Philip A. Thompson,Jan A. Burger,Alessandra Ferrajoli,Zeev Estrov,Susan O’Brien,Michael J. Keating,William G. Wierda,Nitin Jain	2
4	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs 2019 ·Blood Advances ·Preetesh Jain,Hagop M. Kantarjian,Prajwal Boddu,Graciela M. Nogueras‐González,Srđan Verstovšek,Guillermo Garcia‐Manero,Gautam Borthakur,Koji Sasaki,Tapan M. Kadia,(unknown),(unknown),Susan O’Brien,Zeev Estrov,Farhad Ravandi,Elias Jabbour,Jörge E. Cortes	85
5	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype 2019 ·British Journal of Haematology ·Paolo Strati,Feng Wang,Francesco Paolo Tambaro,Philip A. Thompson,Jan A. Burger,Nitin Jain,Alessandra Ferrajoli,Prithviraj Bose,Zeev Estrov,Michael J. Keating,P. Andrew Futreal,Koichi Takahashi,William G. Wierda	1
6	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation 2018 ·Cancer ·Rashmi Kanagal‐Shamanna,Preetesh Jain,Keyur P. Patel,Mark J. Routbort,Carlos E. Bueso‐Ramos,(unknown),Joseph D. Khoury,Rajyalakshmi Luthra,Alessandra Ferrajoli,Michael J. Keating,Nitin Jain,Jan A. Burger,Zeev Estrov,William G. Wierda,Hagop M. Kantarjian,L. Jeffrey Medeiros	77
7	Biclonal IGHV‐4‐34 hairy cell leukemia variant and CLL ‐ successful treatment with ibrutinib and venetoclax 2018 ·American Journal of Hematology ·Preetesh Jain,Rashmi Kanagal‐Shamanna,Sergej Konoplev,Zhuang Zuo,Zeev Estrov	24
8	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation 2018 ·Leukemia Research ·Yasmin Abaza,(unknown),Srđan Verstovšek,(unknown),Farhad Ravandi,Gautam Borthakur,Zeev Estrov,Yesid Alvarado,Jan A. Burger,Heather Schneider,Kelly A. Soltysiak,Yue Wei,Hagop M. Kantarjian,Carlos E. Bueso‐Ramos,Guillermo Garcia‐Manero	8
9	Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex 2017 ·Molecular Cancer Research ·Uri Rozovski,David Harris,Ping Li,Zhiming Liu,Preetesh Jain,(unknown),Alessandra Ferrajoli,Jan A. Burger,Susan O’Brien,Prithviraj Bose,Philip A. Thompson,Nitin Jain,William G. Wierda,Michael J. Keating,Zeev Estrov	23
10	The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab 2017 ·British Journal of Haematology ·Preetesh Jain,Graciela M. Nogueras‐González,Rashmi Kanagal‐Shamanna,Uri Rozovski,(unknown),Constantine S. Tam,William G. Wierda,Philip A. Thompson,Nitin Jain,Rajyalakshmi Luthra,Andres Quesada,(unknown),Alessandra Ferrajoli,Jan A. Burger,Hagop M. Kantarjian,Jörge E. Cortes,Susan O’Brien,Michael J. Keating,Zeev Estrov	23
11	Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib 2017 ·Blood ·Lucia Masárová,Prithviraj Bose,Naveen Pemmaraju,Naval Daver,Jörge E. Cortes,Zeev Estrov,Hagop M. Kantarjian,Srđan Verstovšek	3
12	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Preetesh Jain,Michael J. Keating,William G. Wierda,Mariela Sivina,Philip A. Thompson,Alessandra Ferrajoli,Zeev Estrov,Hagop M. Kantarjian,Susan O’Brien,Jan A. Burger	45
13	Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells 2015 ·Molecular Cancer Research ·Uri Rozovski,Srđana Grgurević,Carlos Bueso-Ramos,David Harris,Ping Li,Zhiming Liu,Ji Yuan Wu,Preetesh Jain,William G. Wierda,Jan A. Burger,Susan O’Brien,Nitin Jain,Alessandra Ferrajoli,Michael J. Keating,Zeev Estrov	69
14	Bone Marrow Stroma–Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor 2011 ·Cancer Research ·Taghi Manshouri,Zeev Estrov,Alfonso Quintás-Cardama,Jan A. Burger,Ying Zhang,(unknown),(unknown),David Harris,Chad J. Creighton,Hagop M. Kantarjian,Srđan Verstovšek	80
15	Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome 2009 ·Clinical Cancer Research ·Wanlong Ma,Hagop M. Kantarjian,B. Nebiyou Bekele,Amber C. Donahue,Xi Zhang,(unknown),Susan O’Brien,Elihu H. Estey,Zeev Estrov,Jörge E. Cortes,Michael J. Keating,Francis J. Giles,Maher Albitar	40
16	Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax) 2008 ·Cancer Research ·Marina Konopleva,Julie C. Watt,Rooha Contractor,Twee Tsao,David Harris,Zeev Estrov,William G. Bornmann,Hagop Kantarjian,Jean Viallet,Ismael Samudio,Michael Andreeff	215
17	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia 2008 ·Blood ·Alessandra Ferrajoli,Bang-Ning Lee,Ellen Schlette,Susan O’Brien,Hui Gao,Sijin Wen,William G. Wierda,Zeev Estrov,Stefan Faderl,Evan N. Cohen,Changping Li,James M. Reuben,Michael J. Keating	304
18	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome 2008 ·Blood ·Stefan Faderl,Farhad Ravandi,Xuelin Huang,Guillermo Garcia‐Manero,Alessandra Ferrajoli,Zeev Estrov,Gautam Borthakur,Srđan Verstovšek,Deborah A. Thomas,Monica Kwari,Hagop M. Kantarjian	151
19	Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia 2001 ·Journal of Clinical Investigation ·Michele Stanislaw Milella,Steven M. Kornblau,Zeev Estrov,(unknown),Hélène Lapillonne,David Harris,Marina Konopleva,Shourong Zhao,Elihu H. Estey,Michael Andreeff	14
20	E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. 2000 ·PubMed ·Naoto T. Ueno,Chandra Bartholomeusz,John L. Herrmann,Zeev Estrov,Ruping Shao,Michael Andreeff,Janet E. Price,Ralph W. Paul,Pervin Anklesaria,Dihua Yu,Mien‐Chie Hung	82

About Zeev Estrov

Zeev Estrov is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 669 papers that have together received 26.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (285 papers), Chronic Lymphocytic Leukemia Research (231 papers) and Chronic Myeloid Leukemia Treatments (184 papers). The work is most often cited by research in Hematology (13.3k citations), Genetics (10.5k citations) and Pathology and Forensic Medicine (3.5k citations). Zeev Estrov has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Hagop M. Kantarjian, Stefan Faderl, Moshe Talpaz, Jörge E. Cortes, Susan O’Brien, Michael J. Keating, Razelle Kurzrock, Alessandra Ferrajoli, Martin Körbling and David Harris. Their work appears in journals such as New England Journal of Medicine, Circulation and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact